EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Target Trial Emulations of GLP ‐1 and Dual GLP ‐1/ GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes

Alex E Henney iD, David R Riley, Matthew Anson, Shazli Azmi, Uazman Alam, Daniel J Cuthbertson

Liver International · 2025

DOI: 10.1111/liv.70367 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Liver International, 2025. Verfasst von Alex E Henney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials suggest GLP‐1 receptor agonists (RAs) and dual glucagon‐like peptide‐1 (GLP‐1)/glucose‐dependent insulinotropic polypeptide (GIP) RAs improve metabolic dysfunction associated with steatohepatitis (MASH) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to compare the estimate of the relative effect of tirzepatide, semaglutide, and liraglutide in reducing the risk of major adverse liver outcomes (MALOs) in patients with type 2 diabetes (T2D). Design, Setting and Participants We emulated target trials based on a real‐world network of electronic health records (EHRs) from over 150 million patients. Three target trials were emulated, among eligible patients with T2D who had no prior MALO diagnosis, by comparing therapy involving tirzepatide, semaglutide, and liraglutide versus DPP4 inhibitor (DPP4i) therapy. We identified the first‐ever diagnosis of MALO occurring within a 2‐year follow‐up period and compared across the treatment groups using Kaplan–Meier survival analyses. Cohorts underwent propensity score matching 1:1 for confounders. We performed sensitivity analyses relating to geographical location, combination with metformin, and by treatment adherence. We also performed head‐to‐head analyses of the incretin‐based therapies.

Results

After matching, we identified three target trials comprised of 10 165, 56 702, and 8 301 patients treated with tirzepatide, semaglutide, and liraglutide, respectively (1:1 with reference patients) for a 2‐year period. Tirzepatide (HR 0.53 [95% CI 0.40, 0.71]) and semaglutide (HR 0.81 [0.72, 0.90]) were associated with a significant reduction in the risk of incident MALO compared with DPP4i, whereas liraglutide was not (HR 1.04 [95% CI 0.79, 1.36]). In head‐to‐head comparisons, tirzepatide was associated with a significantly lower risk of incident MALO compared with liraglutide (HR 0.56 [95% CI 0.39, 0.79]), but not semaglutide (HR 0.83 [95% CI 0.63, 1.09]). Semaglutide was not associated with a reduced risk compared with liraglutide (HR 0.77 [95% CI 0.57, 1.05]).

Conclusion

Treatment with tirzepatide and, to a lesser extent, semaglutide, in patients with T2D, was associated with a lower incidence of MALO compared with DPP4i after 2 years; largely driven by a reduction in the rates of compensated and decompensated cirrhosis. A reduction in MALO was not demonstrated with the use of liraglutide. These findings highlight a comparative benefit of tirzepatide (and semaglutide) versus DPP4i and should prompt more robust, longer‐term randomised controlled studies to evaluate their role in preventing MALO in this increasingly prevalent patient population with co‐existing T2D and MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2LiraglutideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansGlucagon-Like PeptidesMaleFemaleMiddle AgedTirzepatideAgedDipeptidyl-Peptidase IV InhibitorsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsSemaglutide

Substanzen

LiraglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsTirzepatideDipeptidyl-Peptidase IV InhibitorsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsSemaglutide

Autor:innen und Institutionen

  • Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.
  • Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.
  • Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.

ORCID-Profile: Alex E Henney

Zitieren

APA

Henney, A. E., Riley, D. R., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025). Target Trial Emulations of GLP ‐1 and Dual GLP ‐1/ GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver International. https://doi.org/10.1111/liv.70367

Vancouver

Henney AE, Riley DR, Anson M, Azmi S, Alam U, Cuthbertson DJ. Target Trial Emulations of GLP ‐1 and Dual GLP ‐1/ GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver International. 2025. doi:10.1111/liv.70367

BibTeX
@article{Henney2025,
  author = {Henney, Alex E and Riley, David R and Anson, Matthew and Azmi, Shazli and Alam, Uazman and Cuthbertson, Daniel J},
  title = {Target Trial Emulations of GLP ‐1 and Dual GLP ‐1/ GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70367}
}
Kostenlos starten →